Bill to ban limits on prescription drug co-pay help remains stalled in Ohio House

Sara Sharpe, 34, has a pretty basic wish: She doesn’t want to suffer a potentially fatal allergic reaction “because of insurance company paperwork” foul-ups.

She is one of millions nationwide caught up in a money-saving move by health insurance companies with the unwieldy name of “co-pay accumulators.” People in this diverse group, many suffering from rare diseases, are casualties of the ongoing battle over prescription drug prices among multibillion-dollar pharmaceutical manufacturers, health insurers and the obscure middlemen in the drug-supply chain, pharmacy benefit managers.